Nathalie Compagnone is a neuroscientist by training, who obtained her doctorate in 1993 following engineering training at ESA. She was the principal investigator of a research laboratory at the University of California, San Francisco (UCSF) before joining the pharmaceutical industry in 2004. She then led the Huntington's disease preclinical drug development program at Trophos. Nathalie Compagnone specializes in systems biology, molecular and cellular imaging and image analysis. She is also trained in business management and received a certificate in bio entrepreneurship (CBE) from UCSF, an executive MBA from IAE (Aix-en-Provence) and a mini-MBA in industry management from health from Rutgers University. The researcher is also a graduate of HEC modules in executive training. She founded and directed ICDD for 12 years, a company offering innovative decision-making tools to optimize health product development processes. The ICDD has developed diagnostic biomarkers for Alzheimer’s disease. She then founded the BLiiVE consulting group. She also chairs the operations of a company as CRO, mtBiolabs, which provides services to the pharmaceutical and cosmetics industry for the demonstration of activity on mitochondrial targets.
Nathalie COMPAGNONE
